TISIDB

Summary
Symbol	HGF
Name	hepatocyte growth factor (hepapoietin A; scatter factor)
Aliases	F-TCF; HGFB; HPTA; hepatopoietin A; fibroblast-derived tumor cytotoxic factor; scatter factor; lung fibrobla ......
Chromosomal Location	7q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	-
Domain	PF00051 Kringle domain PF00024 PAN domain PF00089 Trypsin
Function	Potent mitogen for mature parenchymal hepatocyte cells, seems to be a hepatotrophic factor, and acts as a growth factor for a broad spectrum of tissues and cell types. Activating ligand for the receptor tyrosine kinase MET by binding to it and promoting its dimerization.

> Gene Ontology [ TOP ]
Biological Process	GO:0000187 activation of MAPK activity GO:0000302 response to reactive oxygen species GO:0001503 ossification GO:0001525 angiogenesis GO:0001649 osteoblast differentiation GO:0001763 morphogenesis of a branching structure GO:0001818 negative regulation of cytokine production GO:0001819 positive regulation of cytokine production GO:0001836 release of cytochrome c from mitochondria GO:0001837 epithelial to mesenchymal transition GO:0001889 liver development GO:0001933 negative regulation of protein phosphorylation GO:0002576 platelet degranulation GO:0006022 aminoglycan metabolic process GO:0006887 exocytosis GO:0006914 autophagy GO:0006979 response to oxidative stress GO:0007067 mitotic nuclear division GO:0007272 ensheathment of neurons GO:0007431 salivary gland development GO:0007435 salivary gland morphogenesis GO:0008366 axon ensheathment GO:0008625 extrinsic apoptotic signaling pathway via death domain receptors GO:0008637 apoptotic mitochondrial changes GO:0010035 response to inorganic substance GO:0010421 hydrogen peroxide-mediated programmed cell death GO:0010466 negative regulation of peptidase activity GO:0010506 regulation of autophagy GO:0010507 negative regulation of autophagy GO:0010639 negative regulation of organelle organization GO:0010720 positive regulation of cell development GO:0010821 regulation of mitochondrion organization GO:0010823 negative regulation of mitochondrion organization GO:0010951 negative regulation of endopeptidase activity GO:0010975 regulation of neuron projection development GO:0010976 positive regulation of neuron projection development GO:0014065 phosphatidylinositol 3-kinase signaling GO:0014066 regulation of phosphatidylinositol 3-kinase signaling GO:0014068 positive regulation of phosphatidylinositol 3-kinase signaling GO:0018105 peptidyl-serine phosphorylation GO:0018108 peptidyl-tyrosine phosphorylation GO:0018209 peptidyl-serine modification GO:0018212 peptidyl-tyrosine modification GO:0022612 gland morphogenesis GO:0030203 glycosaminoglycan metabolic process GO:0030212 hyaluronan metabolic process GO:0030278 regulation of ossification GO:0030335 positive regulation of cell migration GO:0031098 stress-activated protein kinase signaling cascade GO:0031099 regeneration GO:0031100 animal organ regeneration GO:0031102 neuron projection regeneration GO:0031346 positive regulation of cell projection organization GO:0031348 negative regulation of defense response GO:0031641 regulation of myelination GO:0031643 positive regulation of myelination GO:0031644 regulation of neurological system process GO:0031646 positive regulation of neurological system process GO:0032102 negative regulation of response to external stimulus GO:0032147 activation of protein kinase activity GO:0032613 interleukin-10 production GO:0032635 interleukin-6 production GO:0032653 regulation of interleukin-10 production GO:0032675 regulation of interleukin-6 production GO:0032715 negative regulation of interleukin-6 production GO:0032733 positive regulation of interleukin-10 production GO:0032872 regulation of stress-activated MAPK cascade GO:0033135 regulation of peptidyl-serine phosphorylation GO:0033137 negative regulation of peptidyl-serine phosphorylation GO:0033674 positive regulation of kinase activity GO:0034599 cellular response to oxidative stress GO:0034614 cellular response to reactive oxygen species GO:0035272 exocrine system development GO:0035728 response to hepatocyte growth factor GO:0035729 cellular response to hepatocyte growth factor stimulus GO:0036473 cell death in response to oxidative stress GO:0036474 cell death in response to hydrogen peroxide GO:0038066 p38MAPK cascade GO:0040017 positive regulation of locomotion GO:0042326 negative regulation of phosphorylation GO:0042542 response to hydrogen peroxide GO:0042552 myelination GO:0043154 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043405 regulation of MAP kinase activity GO:0043406 positive regulation of MAP kinase activity GO:0043410 positive regulation of MAPK cascade GO:0044057 regulation of system process GO:0045055 regulated exocytosis GO:0045666 positive regulation of neuron differentiation GO:0045667 regulation of osteoblast differentiation GO:0045669 positive regulation of osteoblast differentiation GO:0045765 regulation of angiogenesis GO:0045766 positive regulation of angiogenesis GO:0045778 positive regulation of ossification GO:0045860 positive regulation of protein kinase activity GO:0045861 negative regulation of proteolysis GO:0048012 hepatocyte growth factor receptor signaling pathway GO:0048015 phosphatidylinositol-mediated signaling GO:0048017 inositol lipid-mediated signaling GO:0048514 blood vessel morphogenesis GO:0048732 gland development GO:0048762 mesenchymal cell differentiation GO:0050727 regulation of inflammatory response GO:0050728 negative regulation of inflammatory response GO:0050730 regulation of peptidyl-tyrosine phosphorylation GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation GO:0050769 positive regulation of neurogenesis GO:0050918 positive chemotaxis GO:0051052 regulation of DNA metabolic process GO:0051054 positive regulation of DNA metabolic process GO:0051272 positive regulation of cellular component movement GO:0051346 negative regulation of hydrolase activity GO:0051403 stress-activated MAPK cascade GO:0051450 myoblast proliferation GO:0051962 positive regulation of nervous system development GO:0052547 regulation of peptidase activity GO:0052548 regulation of endopeptidase activity GO:0060326 cell chemotaxis GO:0060445 branching involved in salivary gland morphogenesis GO:0060485 mesenchyme development GO:0060638 mesenchymal-epithelial cell signaling GO:0060665 regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling GO:0060688 regulation of morphogenesis of a branching structure GO:0060693 regulation of branching involved in salivary gland morphogenesis GO:0061008 hepaticobiliary system development GO:0061138 morphogenesis of a branching epithelium GO:0070301 cellular response to hydrogen peroxide GO:0070302 regulation of stress-activated protein kinase signaling cascade GO:0070570 regulation of neuron projection regeneration GO:0070572 positive regulation of neuron projection regeneration GO:0071897 DNA biosynthetic process GO:0071900 regulation of protein serine/threonine kinase activity GO:0071902 positive regulation of protein serine/threonine kinase activity GO:0090199 regulation of release of cytochrome c from mitochondria GO:0090201 negative regulation of release of cytochrome c from mitochondria GO:0097191 extrinsic apoptotic signaling pathway GO:0097468 programmed cell death in response to reactive oxygen species GO:1900407 regulation of cellular response to oxidative stress GO:1900408 negative regulation of cellular response to oxidative stress GO:1900744 regulation of p38MAPK cascade GO:1901031 regulation of response to reactive oxygen species GO:1901032 negative regulation of response to reactive oxygen species GO:1901298 regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901342 regulation of vasculature development GO:1902041 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902882 regulation of response to oxidative stress GO:1902883 negative regulation of response to oxidative stress GO:1902947 regulation of tau-protein kinase activity GO:1903201 regulation of oxidative stress-induced cell death GO:1903202 negative regulation of oxidative stress-induced cell death GO:1903205 regulation of hydrogen peroxide-induced cell death GO:1903206 negative regulation of hydrogen peroxide-induced cell death GO:1903510 mucopolysaccharide metabolic process GO:1904018 positive regulation of vasculature development GO:1905330 regulation of morphogenesis of an epithelium GO:2000027 regulation of organ morphogenesis GO:2000116 regulation of cysteine-type endopeptidase activity GO:2000117 negative regulation of cysteine-type endopeptidase activity GO:2000147 positive regulation of cell motility GO:2000278 regulation of DNA biosynthetic process GO:2000573 positive regulation of DNA biosynthetic process GO:2001233 regulation of apoptotic signaling pathway GO:2001234 negative regulation of apoptotic signaling pathway GO:2001236 regulation of extrinsic apoptotic signaling pathway GO:2001237 negative regulation of extrinsic apoptotic signaling pathway
Molecular Function	GO:0008083 growth factor activity GO:0042056 chemoattractant activity GO:0046982 protein heterodimerization activity
Cellular Component	GO:0030141 secretory granule GO:0031091 platelet alpha granule GO:0031093 platelet alpha granule lumen GO:0031983 vesicle lumen GO:0034774 secretory granule lumen GO:0060205 cytoplasmic membrane-bounded vesicle lumen GO:0099503 secretory vesicle

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04014 Ras signaling pathway hsa04015 Rap1 signaling pathway hsa04060 Cytokine-cytokine receptor interaction hsa04151 PI3K-Akt signaling pathway hsa04510 Focal adhesion
Reactome	R-HSA-170984: ARMS-mediated activation R-HSA-1280218: Adaptive Immune System R-HSA-422475: Axon guidance R-HSA-2219530: Constitutive Signaling by Aberrant PI3K in Cancer R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-2172127: DAP12 interactions R-HSA-2424491: DAP12 signaling R-HSA-1266738: Developmental Biology R-HSA-1643685: Disease R-HSA-5663202: Diseases of signal transduction R-HSA-186763: Downstream signal transduction R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR) R-HSA-2871796: FCERI mediated MAPK activation R-HSA-2454202: Fc epsilon receptor (FCERI) signaling R-HSA-170968: Frs2-mediated activation R-HSA-180292: GAB1 signalosome R-HSA-179812: GRB2 events in EGFR signaling R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK R-HSA-109582: Hemostasis R-HSA-2428924: IGF1R signaling cascade R-HSA-112399: IRS-mediated signalling R-HSA-2428928: IRS-related events triggered by IGF1R R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-74751: Insulin receptor signalling cascade R-HSA-912526: Interleukin receptor SHC signaling R-HSA-451927: Interleukin-2 signaling R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling R-HSA-6785807: Interleukin-4 and 13 signaling R-HSA-1266695: Interleukin-7 signaling R-HSA-5683057: MAPK family signaling cascades R-HSA-5684996: MAPK1/MAPK3 signaling R-HSA-6806942: MET Receptor Activation R-HSA-8851907: MET activates PI3K/AKT signaling R-HSA-8874081: MET activates PTK2 signaling R-HSA-8865999: MET activates PTPN11 R-HSA-8875555: MET activates RAP1 and RAC1 R-HSA-8851805: MET activates RAS signaling R-HSA-8875791: MET activates STAT3 R-HSA-8875513: MET interacts with TNS proteins R-HSA-8875878: MET promotes cell motility R-HSA-8875656: MET receptor recycling R-HSA-375165: NCAM signaling for neurite out-growth R-HSA-187037: NGF signalling via TRKA from the plasma membrane R-HSA-6807004: Negative regulation of MET activity R-HSA-199418: Negative regulation of the PI3K/AKT network R-HSA-2219528: PI3K/AKT Signaling in Cancer R-HSA-198203: PI3K/AKT activation R-HSA-6811558: PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling R-HSA-1257604: PIP3 activates AKT signaling R-HSA-76002: Platelet activation, signaling and aggregation R-HSA-114608: Platelet degranulation R-HSA-169893: Prolonged ERK activation events R-HSA-5673001: RAF/MAP kinase cascade R-HSA-8853659: RET signaling R-HSA-76005: Response to elevated platelet cytosolic Ca2+ R-HSA-2730905: Role of LAT2/NTAL/LAB on calcium mobilization R-HSA-180336: SHC1 events in EGFR signaling R-HSA-112412: SOS-mediated signalling R-HSA-162582: Signal Transduction R-HSA-177929: Signaling by EGFR R-HSA-372790: Signaling by GPCR R-HSA-74752: Signaling by Insulin receptor R-HSA-449147: Signaling by Interleukins R-HSA-2586552: Signaling by Leptin R-HSA-6806834: Signaling by MET R-HSA-186797: Signaling by PDGF R-HSA-1433557: Signaling by SCF-KIT R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) R-HSA-194138: Signaling by VEGF R-HSA-983705: Signaling by the B Cell Receptor (BCR) R-HSA-166520: Signalling by NGF R-HSA-187687: Signalling to ERKs R-HSA-167044: Signalling to RAS R-HSA-187706: Signalling to p38 via RIT and RIN R-HSA-4420097: VEGFA-VEGFR2 Pathway R-HSA-5218921: VEGFR2 mediated cell proliferation

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04014 Ras signaling pathway
hsa04015 Rap1 signaling pathway
hsa04060 Cytokine-cytokine receptor interaction
hsa04151 PI3K-Akt signaling pathway
hsa04510 Focal adhesion

Reactome

R-HSA-170984: ARMS-mediated activation
R-HSA-1280218: Adaptive Immune System
R-HSA-422475: Axon guidance
R-HSA-2219530: Constitutive Signaling by Aberrant PI3K in Cancer
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-186763: Downstream signal transduction
R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR)
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-170968: Frs2-mediated activation
R-HSA-180292: GAB1 signalosome
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-109582: Hemostasis
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-1266695: Interleukin-7 signaling
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-6806942: MET Receptor Activation
R-HSA-8851907: MET activates PI3K/AKT signaling
R-HSA-8874081: MET activates PTK2 signaling
R-HSA-8865999: MET activates PTPN11
R-HSA-8875555: MET activates RAP1 and RAC1
R-HSA-8851805: MET activates RAS signaling
R-HSA-8875791: MET activates STAT3
R-HSA-8875513: MET interacts with TNS proteins
R-HSA-8875878: MET promotes cell motility
R-HSA-8875656: MET receptor recycling
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-6807004: Negative regulation of MET activity
R-HSA-199418: Negative regulation of the PI3K/AKT network
R-HSA-2219528: PI3K/AKT Signaling in Cancer
R-HSA-198203: PI3K/AKT activation
R-HSA-6811558: PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
R-HSA-1257604: PIP3 activates AKT signaling
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-114608: Platelet degranulation
R-HSA-169893: Prolonged ERK activation events
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-76005: Response to elevated platelet cytosolic Ca2+
R-HSA-2730905: Role of LAT2/NTAL/LAB on calcium mobilization
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-6806834: Signaling by MET
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation

Summary
Symbol	HGF
Name	hepatocyte growth factor (hepapoietin A; scatter factor)
Aliases	F-TCF; HGFB; HPTA; hepatopoietin A; fibroblast-derived tumor cytotoxic factor; scatter factor; lung fibrobla ......
Chromosomal Location	7q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between HGF and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between HGF and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
19588506	Colon Carcinoma	Inhibit immunity (T cell function)	Gene transfer of NK4, an angiogenesis inhibitor, induces CT26 tumor regression via tumor-specific T lymphocyte activation. Hepatocyte growth factor (HGF) has been shown to be involved in malignant behaviors, such as invasion and metastasis, in different tumors. Hepatocyte growth factor (HGF) has been shown to be involved in malignant behaviors, such as invasion and metastasis, in different tumors. NK4 is a competitive antagonist for HGF and exerts an antitumor activity, not only by HGF antagonism but also by antiangiogenesis. Depletion of CD8+ T lymphocytes markedly abrogated the antitumor activity of NK4.
29634978	Squamous Cell Carcinoma	Inhibit immunity	MET/hepatocyte growth factor (HGF) signaling and transcription factors involved in epithelial-to-mesenchymal transition (EMT) upregulate PD-L1, which can contribute to clinical outcome.
18829539	Medulloblastoma	Inhibit immunity	Hepatocyte growth factor and sonic Hedgehog expression in cerebellar neural progenitor cells costimulate medulloblastoma initiation and growth. HGF is neuroprotective for cerebellar granule cells and promotes growth of human medulloblastoma cells in culture and in murine xenografts. Systemic administration of a monoclonal antibody against HGF prolonged survival of mice bearing Shh + HGF-induced medulloblastomas by stimulating apoptosis.

Summary
Symbol	HGF
Name	hepatocyte growth factor (hepapoietin A; scatter factor)
Aliases	F-TCF; HGFB; HPTA; hepatopoietin A; fibroblast-derived tumor cytotoxic factor; scatter factor; lung fibrobla ......
Chromosomal Location	7q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of HGF in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	HGF
Name	hepatocyte growth factor (hepapoietin A; scatter factor)
Aliases	F-TCF; HGFB; HPTA; hepatopoietin A; fibroblast-derived tumor cytotoxic factor; scatter factor; lung fibrobla ......
Chromosomal Location	7q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of HGF in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.464	0.383
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.716	0.0827
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.445	0.611
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.241	0.626
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.055	0.971
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.479	0.793
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.623	0.227
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.957	0.28
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.204	0.839
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.576	0.677
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.034	0.985
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.245	0.29

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of HGF in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	6.8	4.3	0.443
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	6.8	4.3	0.673
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	19	5.9	13.1	0.355
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	23.1	9.1	14	0.596
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	3.7	-1.1	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	7.7	-3.2	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	HGF
Name	hepatocyte growth factor (hepapoietin A; scatter factor)
Aliases	F-TCF; HGFB; HPTA; hepatopoietin A; fibroblast-derived tumor cytotoxic factor; scatter factor; lung fibrobla ......
Chromosomal Location	7q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HGF. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	HGF
Name	hepatocyte growth factor (hepapoietin A; scatter factor)
Aliases	F-TCF; HGFB; HPTA; hepatopoietin A; fibroblast-derived tumor cytotoxic factor; scatter factor; lung fibrobla ......
Chromosomal Location	7q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HGF. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HGF. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	HGF
Name	hepatocyte growth factor (hepapoietin A; scatter factor)
Aliases	F-TCF; HGFB; HPTA; hepatopoietin A; fibroblast-derived tumor cytotoxic factor; scatter factor; lung fibrobla ......
Chromosomal Location	7q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HGF. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	HGF
Name	hepatocyte growth factor (hepapoietin A; scatter factor)
Aliases	F-TCF; HGFB; HPTA; hepatopoietin A; fibroblast-derived tumor cytotoxic factor; scatter factor; lung fibrobla ......
Chromosomal Location	7q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of HGF expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	HGF
Name	hepatocyte growth factor (hepapoietin A; scatter factor)
Aliases	F-TCF; HGFB; HPTA; hepatopoietin A; fibroblast-derived tumor cytotoxic factor; scatter factor; lung fibrobla ......
Chromosomal Location	7q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between HGF and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	HGF
Name	hepatocyte growth factor (hepapoietin A; scatter factor)
Aliases	F-TCF; HGFB; HPTA; hepatopoietin A; fibroblast-derived tumor cytotoxic factor; scatter factor; lung fibrobla ......
Chromosomal Location	7q21.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting HGF collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting HGF.

ID	Name	Drug Type	Targets	#Targets
DB01109	Heparin	Small Molecule	F10, FGF1, FGF19, FGF2, FGF4, FGFR1, FGFR2, FGFR4, HGF, PF4, SELP, ......	12
DB02264	O2-Sulfo-Glucuronic Acid	Small Molecule	FGF1, HGF, HS3ST3A1	3
DB03959	N,O6-Disulfo-Glucosamine	Small Molecule	ANXA5, FGF1, FGF2, HGF, HS3ST3A1	5
DB05434	ABT-510	Small Molecule	CXCL8, FGF2, HGF, VEGFA	4
DB12307	Foretinib	Small Molecule	HGF, KDR	2

Browse HGF